The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review
Open accessAbstract
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) has been implicated as a cause of hepatocellular carcinoma (HCC). We performed a systematic review of epidemiology studies to confirm the association between these disorders. METHODS: We searched PubMed for original reports published from January 1992 to December 2011 that evaluated the association between NAFLD, nonalcoholic steatohepatitis (NASH), cryptogenic cirrhosis presumed to be NASH-related, and the risk of HCC. Studies were categorized as offering potential direct evidence (eg, cohort studies) or indirect evidence (eg, case-control, cross-sectional, or case-series studies) for an association. We analyzed data from a total of 17 cohort studies (3 population based, 9 clinic based [6 limited to patients with cirrhosis], and 5 natural history), 18 case-control and cross-sectional studies, and 26 case series. RESULTS: NAFLD or NASH cohorts with few or no cases of cirrhosis cases had a minimal risk for HCC (cumulative HCC mortality of 0%-3% for study periods up to 20 y). Cohorts with NASH and cirrhosis had a consistently higher risk (cumulative incidence ranging from 2.4% over 7 y to 12.8% over 3 y). However, the risk for HCC was substantially lower in these cohorts than for cohorts with hepatitis C-related cirrhosis. Factors that increased risk among cohorts with NASH and cirrhosis could not be determined, because most studies were not sufficiently powered for multivariate analysis. CONCLUSIONS: This systematic review shows that despite several limitations, there is epidemiologic evidence to support an association between NAFLD or NASH and an increased risk of HCC; risk seems to be limited to individuals with cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A systematic review and a metaanalysis concluded that the risk estimate is likely too low to justify routine screening in MASLD without evidence of advanced fi brosis. 241”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [241]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the HCC incidence in individuals without cirrhosis is very low, ranging from 0.08 to 0.63 per 1,000 PY. 240 -244”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [241]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,182
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,304
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 773
Schattenberg, J. M., & Lee, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.064 · Cited by 18
Öztürk, O. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i26.8096 · Cited by 18
Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance
Zhuo, Y., Chen, Q., & Chhatwal, J. (2019) · Molecular and translational medicine · doi:10.1007/978-3-030-21540-8_3 · Cited by 20
Yoshimine, Y., Uto, H., Kumagai, K., Mawatari, S., Arima, S., Ibusuki, R., Mera, K., Nosaki, T., Kanmura, S., Numata, M., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.3745 · Cited by 18
Pereyra, D., Offensperger, F., Klinglmueller, F., Haegele, S., Oehlberger, L., Gruenberger, T., Brostjan, C., & Starlinger, P. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175359 · Cited by 18
Wang, X., Zhou, Z., Zhang, T., Wang, M., Xu, R., Qin, S., & Zhang, S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s188658 · Cited by 17
Xie, X., Zheng, M., Guo, W.-B., Zhou, Y., Xiang, Z., Li, Y.-T., & Yang, J.-H. (2022) · Scientific Reports · doi:10.1038/s41598-022-18197-6 · Cited by 14
Hu, R., Yang, X., He, X., & Song, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-022-01771-2 · Cited by 18
Stein, S. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182932e6f · Cited by 17
Kwak, H. A., Park, J., Koh, Y. H., Lee, J. H., Yu, A., & Nam, B. (2015) · Liver Cancer · doi:10.1159/000367756 · Cited by 17
Tsuduki, T., Yamamoto, K., Hatakeyama, Y., & Sakamoto, Y. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500736 · Cited by 17
Deng, L. X., & Mehta, N. J. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06550-6 · Cited by 18
Gu, J., Yao, M., Yang, J., Cai, Y., Zheng, W., Wang, L., Yao, D.-B., & Yao, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i2.256 · Cited by 17
NAFLD Induction Delays Postoperative Liver Regeneration of ALPPS in Rats
Zhao, J., Xu, H., Li, Y., Gong, L., Zheng, G., Wang, X., Luan, W., Li, S., Ma, F., Ni, L., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5346-3 · Cited by 17
Bell, M. M., Turkbey, E. B., & Escorcia, F. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000435 · Cited by 17
Lin, A., Xiong, M., Tang, B., Jiang, A., Shen, J., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2025) · Hepatology International · doi:10.1007/s12072-025-10838-y · Cited by 17
Plant-based foods and hepatocellular carcinoma: A review on mechanistic understanding
Saeed, R. A., Maqsood, M., Saeed, R. A., Muzammil, H. S., Khan, M. I., Asghar, L., Nisa, S. U., Rabail, R., & Aadil, R. M. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2095974 · Cited by 17
Modulatory effects of bisphenol A on the hepatic immune response
Gebru, Y. A., & Pang, M. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122430 · Cited by 16
Inokawa, Y., Inaoka, K., Sonohara, F., Hayashi, M., Kanda, M., & Nomoto, S. (2016) · Oncology Letters · doi:10.3892/ol.2016.5141 · Cited by 16
Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma
Qiu, X., Wang, X., Song, Y.-C., & Chen, L. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4270-7 · Cited by 16
Circulating Bile Acid Profiles: A Need for Further Examination
Li, Q., Tian, Y., & Chen, Y. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab531 · Cited by 16
Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach
Orlandi, P., Solini, A., Banchi, M., Brunetto, M. R., Cioni, D., Ghiadoni, L., & Bocci, G. (2021) · Pharmaceuticals · doi:10.3390/ph14100995 · Cited by 15
Cinnabarinic Acid Provides Hepatoprotection Against Nonalcoholic Fatty Liver Disease
Patil, N. Y., Rus, I., Downing, E., Mandala, A., Friedman, J. E., & Joshi, A. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001301 · Cited by 17
Long-Term Outcomes of Nonalcoholic Fatty Liver Disease
Kwak, M., & Kim, D. (2015) · Current Hepatology Reports · doi:10.1007/s11901-015-0258-6 · Cited by 16
A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls
Muzio, F. D., Grassi, F., Dell’Aversana, F., Fusco, R., Danti, G., Flammia, F., Chiti, G., Valeri, T., Agostini, A., Palumbo, P., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12071655 · Cited by 15
Otsubo, N., Fukuda, T., Cho, G., Ishibashi, F., Yamada, T., & Monzen, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.1097-22 · Cited by 15
Yilmaz, Y. N. (2023) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0011 · Cited by 15
Arvanitakis, K., Papadakos, S. P., Lekakis, V., Koufakis, T., Lempesis, I. G., Papantoniou, E., Kalopitas, G., Georgakopoulou, V., Stergiou, I. Ε., Theocharis, S. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914704 · Cited by 16
Yang, Y., Fan, G., Lan, J., Li, X., Li, X., & Liu, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135566 · Cited by 16
Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Case–Control Studies
Yuan, J., Wang, Y., Wang, R., Luu, H. N., Adams‐Haduch, J. M., Koh, W., Gao, Y., Behari, J., & Lotze, M. T. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1081 · Cited by 15
Li, Q., Dai, W., Kong, J., Tian, Y., & Chen, Y. (2021) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-020-00782-w · Cited by 15
Ablation therapy for hepatocellular carcinoma: past, present and future perspectives
Niemeyer, D. J., Simo, K. A., Iannitti, D. A., & McKillop, I. H. (2013) · Hepatic Oncology · doi:10.2217/hep.13.8 · Cited by 15
Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?
Hatton, G. B., Alterio, T., Nobili, V., & Mann, J. P. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1512853 · Cited by 15
Carvalho-Furtado, A. C. L., Carvalho-Louro, D. M., Regattieri, N. A. T., Rodrigues, M. P., Montenegro, M. L. R. N., Ferro, A. M., Pirangi, P. S., & Naves, L. A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00364 · Cited by 15
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma
Simon, T. G., & Chan, A. T. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.06.002 · Cited by 15
Past, Present, and Future of Hepatitis B and Fatty Liver in Bangladesh
Alam, S. (2017) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2017.06.00197 · Cited by 15
Yan, R., & Cao, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13010206 · Cited by 14
van Mourik, H., Li, M., Baumgartner, S., Theys, J., & Shiri‐Sverdlov, R. (2022) · Biomedicines · doi:10.3390/biomedicines10102351 · Cited by 16
Lin, Z.-Y., Zhang, X., Zhao, G., Li, C., Wang, Z.-H., Liu, R., & Hu, M. (2023) · BMC Surgery · doi:10.1186/s12893-023-02058-8 · Cited by 14
Obesity under the moonlight of c-MYC
Nevzorova, Y. A., & Cubero, F. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1293218 · Cited by 16
Global and Country-Level Analysis of Liver Cancer: Disease Burden and Recent Trends
Chen, L., Zhang, J., Peng, J., Yuan, Y., Ding, Y., Wang, Y., & He, X. (2025) · Current Medical Science · doi:10.1007/s11596-025-00064-w · Cited by 14
Ortíz, J. E. P., Santiago Sánchez, P., Prieto, R. G., Díaz, E. L. R., González, L., & Mendivelso, F. (2016) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.66 · Cited by 14
Liebig, M., Hassanzada, A., Kämmerling, M. W., Genz, B., Vollmar, B., & Abshagen, K. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217738730 · Cited by 14
Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma
Martin, M. S., Guillén, J. R. O., Cano, A. P., & Ramia, J. M. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.6640/2019 · Cited by 14
Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients
dos Santos, L. R., & Filho, R. B. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100028 · Cited by 14
Alansari, W. S., & Eskandrani, A. A. (2020) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-020-04478-7 · Cited by 14
Micronutrient Food Supplements in Patients with Gastro-Intestinal and Hepatic Cancers
Alam, W., Ullah, H., Santarcangelo, C., Minno, A. D., Khan, H. Z., Daglia, M., & Arciola, C. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158014 · Cited by 15
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15
New insights on hepatocellular carcinoma: epidemiology and clinical aspects
Puoti, C. (2018) · Hepatoma Research · doi:10.20517/2394-5079.2018.67 · Cited by 14
Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
Tsoulfas, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3842 · Cited by 16
L-Lysine Attenuates Hepatic Steatosis in Senescence-Accelerated Mouse Prone 8 Mice
Sato, T., Muramatsu, N., Ito, Y., Yamamoto, Y., & NAGASAWA, T. (2018) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.64.192 · Cited by 13
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Song, B. G., Kim, A., Goh, M. J., Kang, W., Gwak, G., Paik, Y., Choi, M. S., Lee, J. H., & Sinn, D. H. (2024) · Liver Cancer · doi:10.1159/000538301 · Cited by 13
Wang, J., Du, J., Wang, M., Jin, M., Tang, Z., & Mao, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1509232 · Cited by 13
Ramos-López, O., Riezu‐Boj, J. I., Milagro, F. I., Martínez, J. A., & On Behalf of the MENA Project (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1531136 · Cited by 13
Common Genetic Variants and Nonalcoholic Fatty Liver Disease
Browning, J. D. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.05.013 · Cited by 13
Management and diagnosis of fatty liver disease
Schneier, A., Citti, C., & Dieterich, D. T. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1003209 · Cited by 13
Joliat, G., Hahnloser, D., Demartines, N., & Schäfer, M. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14188 · Cited by 13
Yan, J., Yu, Y., Kang, J. W., Tam, Z. Y., Xu, S., Fong, E. L. S., Singh, S. P., Song, Z., Tucker‐Kellogg, L., So, P. T. C., et al. (2017) · Journal of Biophotonics · doi:10.1002/jbio.201600303 · Cited by 13
Non-Alcoholic Steatohepatitis, Liver Cirrhosis and Hepatocellular Carcinoma: The Molecular Pathways
Mezale, D., Štrumfa, I., Vanags, A., Mežals, M., Fridrihsone, I., Štrumfs, B., & Balodis, D. (2017) · InTech eBooks · doi:10.5772/intechopen.68771 · Cited by 13
Modifiers of Liver-Related Manifestation in the Course of NAFLD
Nasr, P., Blomdahl, J., Kechagias, S., & Ekstedt, M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200310142803 · Cited by 13
Straś, W., Małkowski, P., & Tronina, O. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.99506 · Cited by 13
Hepatocellular Carcinoma in India
Chavda, H. (2021) · Indian Journal of Surgery · doi:10.1007/s12262-021-02762-w · Cited by 13
Banini, B. A., & Roberts, L. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-13614-1_22 · Cited by 13
Nonalcoholic Fatty Liver Disease and Fibrosis Progression: The Good, the Bad, and the Unknown
Harrison, S. A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.024 · Cited by 13
Tang, S., Wu, J., Xu, S., Li, Q., & He, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1071085 · Cited by 13
Therapeutic potential of Phycocyanin in gastrointestinal cancers and related disorders
Motamedzadeh, A., Rahmati‐Dehkordi, F., Heydari, H., Behnam, M., Noshabad, F. Z. R., Tamtaji, Z., Taheri, A. T., Nabavizadeh, F., Aschner, M., Mirzaei, H., et al. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09675-3 · Cited by 12
Lan, T., & Tacke, F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156015 · Cited by 15
Wu, G., Wang, K., Xue, Y., Song, G., Wang, Y., Sun, X., Zhong, L., Zhou, C., Shen, B., Chen, J., et al. (2015) · Gene · doi:10.1016/j.gene.2015.09.007 · Cited by 12
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Cho, Y., Kim, B. H., & Park, J. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0360 · Cited by 12
Siddique, O., Joseph-Talreja, M., Yoo, E. R., Perumpail, R. B., Cholankeril, G. T., Harrison, S. A., Younossi, Z. M., Wong, R. J., & Ahmed, A. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00003 · Cited by 12
Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis
Lewis, R. H., Glazer, E. S., Bittenbinder, D. M., O’Brien, T., Deneve, J. L., Shibata, D., Behrman, S. W., Vanatta, J. M., Satapathy, S. K., & Dickson, P. V. (2018) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-018-0152-x · Cited by 12
Gerhard, G. S., Davis, B., Wu, X., Hanson, A., Wilhelmsen, D., Piras, I. S., Still, C. D., Chu, X., Petrick, A. T., & DiStefano, J. K. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100753 · Cited by 12
Recent advances in live cell imaging of hepatoma cells
Salipalli, S., Singh, P. K., & Borlak, J. T. (2014) · BMC Cell Biology · doi:10.1186/1471-2121-15-26 · Cited by 12
Fukuda, K., Seki, Y., Ichihi, M., Okada, T., Hirata, A., Kogita, S., Sawai, Y., Igura, T., Tsugawa, M., & Imai, Y. (2015) · Journal of Medical Ultrasonics · doi:10.1007/s10396-015-0615-7 · Cited by 12
Hard clinical outcomes in patients with NAFLD
Kumar, R. K. (2013) · Hepatology International · doi:10.1007/s12072-013-9455-y · Cited by 12
Editorial: NAFLD‐related hepatocellular carcinoma ‐ increasing or not? With or without cirrhosis?
Balakrishnan, M., & El‐Serag, H. B. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14464 · Cited by 12
Epidemiology and Risk Factors of Hepatocellular Carcinoma
El‐Serag, H. B., Balakrishnan, M., & Natarajan, Y. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch14 · Cited by 13
Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease
Shrestha, A., & Pradhananga, S. (2022) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1359 · Cited by 11
Bilirubin metabolism in relation to cancer
Yi, F., Tao, S., & Wu, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570288 · Cited by 11
Al-Awadhi, S. S. A., Patil, P., Shetty, P., Shetty, P. K., Shetty, R. A., & Shetty, V. V. (2025) · Bioimpacts · doi:10.34172/bi.30905 · Cited by 12
Systemic Therapy for Hepatocellular Carcinoma and Cholangiocarcinoma
Chung, V. M. (2014) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.09.009 · Cited by 11
Surveillance for Hepatocellular Carcinoma
Ramachandran, J. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.03.050 · Cited by 11
Non-Invasive Photothermal Strain Imaging of Non-Alcoholic Fatty Liver Disease in Live Animals
Choi, C., Choi, W., Kim, J., & Kim, C. (2021) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2021.3081097 · Cited by 11
Alteration in immune function in patients with fatty liver disease
Gregory, S. N., Perati, S. R., & Brown, Z. J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.34 · Cited by 11
Costante, F., Airola, C., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1622 · Cited by 12
Compagnoni, C., Capelli, R., Zelli, V., Corrente, A., Vecchiotti, D., Flati, I., Nolfi, M. D. V., Angelucci, A., Alesse, E., Zazzeroni, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119239 · Cited by 12
Clinical Features of Pediatric Nonalcoholic Fatty Liver Disease
Middleton, J. P., Wiener, R. C., Barnes, B. H., Gurka, M. J., & DeBoer, M. D. (2014) · Clinical Pediatrics · doi:10.1177/0009922813520072 · Cited by 11
Ghinolfi, D., Rreka, E., Pezzati, D., Filipponi, F., & SIMONE, P. D. (2017) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2017.10.01 · Cited by 11
HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time
Sokolich, J. C., Buggs, J., LaVere, M. G., Robichaux, K., Rogers, E., Nyce, S., Kumar, A., & Bowers, V. D. (2020) · The American Surgeon · doi:10.1177/0003134820942165 · Cited by 11
Wang, Y., Liu, Z., Zou, W., Hong, H., Fang, H., & Tong, W. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.70 · Cited by 11
A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report
Ōno, M., Sawada, K., & Okumura, T. (2016) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-016-0705-0 · Cited by 11
Role of glycoprotein 78 and cidec in hepatic steatosis
Li, J., Liu, G., Zhang, F., Zhang, Z., Xu, Y., & Li, Q. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6834 · Cited by 11
Mrzljak, A., Berković, M. C., Giovanardi, F., & Lai, Q. (2022) · Croatian Medical Journal · doi:10.3325/cmj.2022.63.176 · Cited by 10
Liang, Y., Ye, X., Pan, M., Chen, Y., Yuan, Y., & Luo, L. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03661-0 · Cited by 10
Lequoy, M., Gigante, E., Couty, J., & Desbois‐Mouthon, C. (2020) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2019-0044 · Cited by 12
The effects of the voglibose on non-alcoholic fatty liver disease in mice model
Bae, J., Lee, J. Y., Shin, E., Lee, M., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-15550-7 · Cited by 10
Alomari, M., Rashid, M. U., Chadalavada, P. N., Ragheb, J. G., Zafar, H., Suarez, Z. K., Khazaaleh, S., Gonzalez, A. J., & Castro, F. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.477 · Cited by 11
Epidemiological Trends in NASH as a Cause for Liver Transplant
Siow, W., van der Poorten, D., & George, J. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0294-x · Cited by 10
Mohsen, W., Rodov, M., Prakoso, E., Charlton, B., Bowen, D. G., Koorey, D. J., Shackel, N. A., McCaughan, G. W., & Strasser, S. I. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i15.2763 · Cited by 10
Lu, J., Nguyen, L., Samadzadeh, S., Masouminia, M., Mendoza, A. S., Sweeney, O., Tillman, B. C., Afifiyan, N. F., Morgan, T. R. M., French, B. A., et al. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.02.001 · Cited by 10
Metadata
- Authors
- White, D. L., Kanwal, F., & El–Serag, H. B.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- White, Donna L.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 10
- Issue
- 12
- Pages
- 1342-1359.e2
- ISSN
- 1542-3565 (ISSN-L)
- PMC
- PMC3501546
- OpenAlex
- W1975567145
- Cited by
- 766
- References
- 73
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 39 · 2023: 49 · 2022: 61 · 2021: 71 · 2020: 68 · 2019: 64 · 2018: 76 · 2017: 73 · 2016: 54 · 2015: 58 · 2014: 54 · 2013: 56
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (HFP90-020, DK56338)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK56338, K24DK078154, K24 DK081736-01, K01 DK078154-03, K01DK081736, P30DK056338)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, cryptogenic cirrhosis, cancer risk, HCC mortality
- MeSH terms
- Fatty Liver, Humans, Liver Neoplasms, Risk Assessment, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
